Published in Transplantation on November 15, 2005
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae (2011) 1.19
Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol (2011) 1.16
Treating rheumatic patients with a malignancy. Arthritis Res Ther (2011) 1.03
Malignancies in systemic lupus erythematosus. Autoimmun Rev (2009) 1.02
Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol (2010) 0.98
Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J (2015) 0.97
Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol (2011) 0.92
EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil. Neuro Oncol (2007) 0.92
Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation (2015) 0.90
Incidence of malignancy after living kidney transplantation: a multicenter study from iran. J Cancer (2012) 0.89
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep (2013) 0.89
Histone deacetylase inhibitors and transplantation. Curr Opin Immunol (2007) 0.87
Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant (2011) 0.87
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant (2008) 0.86
Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatr Nephrol (2011) 0.86
The mortality risk with graft function has decreased among children receiving a first kidney transplant in the United States. Kidney Int (2014) 0.86
Post-transplant lymphoproliferative disease. Pediatr Nephrol (2007) 0.86
New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs (2014) 0.84
Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II. Dig Dis Sci (2008) 0.84
Posttransplant lymphoproliferative disease after pediatric solid organ transplantation. Clin Dev Immunol (2013) 0.83
PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. Am J Transplant (2013) 0.81
Spectrum of lymphoproliferative disorders following renal transplantation in North India. Indian J Nephrol (2013) 0.80
Successful treatment with lenalidomide of secondary multiple myeloma with extramedullary liver plasmacytoma in a renal transplant recipient: A case report and review of the literature. Oncol Lett (2015) 0.80
Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol (2014) 0.80
Malignancies after pediatric kidney transplantation: more than PTLD? Pediatr Nephrol (2013) 0.78
Selective late steroid withdrawal after renal transplantation. Pediatr Nephrol (2007) 0.78
Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience. Clin Dev Immunol (2013) 0.77
Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today (2012) 0.77
Cyclosporin-A associated malignancy. Clin Ophthalmol (2007) 0.76
Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. Trials (2015) 0.76
Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant. Am J Transplant (2016) 0.76
Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget (2015) 0.76
HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort. Transplant Direct (2015) 0.75
Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation. Transplant Res (2016) 0.75
Steroid-resistant acute allograft rejection in renal transplantation. Pediatr Nephrol (2011) 0.75
Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. Clin Lymphoma Myeloma Leuk (2016) 0.75
HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation. Transplantation (2016) 0.75
Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol (2015) 0.75
Lowered Immune Cell Function in Liver Recipients Recovered From Posttransplant Lymphoproliferative Disease Who Developed Graft Tolerance. Transplant Direct (2016) 0.75
A de novo monoclonal immunoglobulin deposition disease in a kidney transplant recipient: a case report. J Med Case Rep (2014) 0.75
Post-transplantation primary central nervous system lymphoma: A case report and review of the literature. Surg Neurol Int (2011) 0.75
Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med (Cali) (2016) 0.75
Post cardiac transplantation T-cell lymphoproliferative disorder presenting as a solitary lung nodule. Int J Clin Exp Pathol (2013) 0.75
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75
Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). Exp Toxicol Pathol (2013) 0.75
A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders. Clin J Am Soc Nephrol (2017) 0.75
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol (2017) 0.75
Contribution of solid organ transplant recipients to the pediatric non-hodgkin lymphoma burden in the United States. Cancer (2017) 0.75
Relapsing EBV encephalitis in a renal transplant recipient. IDCases (2017) 0.75
'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis (2012) 5.70
Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis (2010) 3.11
US Renal Data System 2010 Annual Data Report. Am J Kidney Dis (2011) 2.90
Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis (2005) 2.81
US Renal Data System 2013 Annual Data Report. Am J Kidney Dis (2014) 2.68
US Renal Data System 2012 Annual Data Report. Am J Kidney Dis (2013) 2.54
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol (2003) 2.21
Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis (2007) 2.16
United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis (2009) 2.14
Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol (2005) 2.07
Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis (2008) 2.01
Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol (2003) 1.84
Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis (2003) 1.70
Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol (2003) 1.56
Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998-2000. Am J Transplant (2004) 1.52
Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med (2002) 1.43
Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol (2008) 1.20
Validation of creatinine assays utilizing HPLC and IDMS traceable standards in sera of children. Pediatr Nephrol (2008) 1.20
Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis (2008) 1.15
Racial disparities in renal replacement therapy. J Natl Med Assoc (2002) 1.15
New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation (2005) 1.06
The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol (2008) 1.04
Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis (2002) 1.03
Racial disparities in kidney health: the puzzle to solve. Am J Kidney Dis (2002) 0.95
Global approaches for understanding the disproportionate burden of chronic kidney disease. Ethn Dis (2009) 0.93
Incidence, predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients. Urology (2011) 0.93
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int Suppl (2003) 0.91
The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol (2013) 0.89
Racial differences and income disparities are associated with poor outcomes in kidney transplant recipients with lupus nephritis. Transplantation (2013) 0.85
Hypertensive chronic kidney disease in African Americans: strategies for improving care. Cleve Clin J Med (2012) 0.82
Viral immune monitoring for post-transplant lymphoproliferative disorder. Pediatr Transplant (2009) 0.81
Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease. BMC Nephrol (2014) 0.81
Kidney disease in disadvantaged populations. Int J Nephrol (2012) 0.79
Renal replacement therapy in support of Operation Iraqi Freedom: a tri-service perspective. Mil Med (2008) 0.79
Cardiorenal metabolic syndrome in the African diaspora: rationale for including chronic kidney disease in the metabolic syndrome definition. Ethn Dis (2009) 0.78
Ethnic disparities in the prevalence and treatment of kidney disease. Nephrol News Issues (2004) 0.77
Effect of intensive blood pressure control on cardiovascular remodeling in hypertensive patients with nephrosclerosis. Int J Nephrol (2013) 0.76
Medication compliance in transplantation. Am J Transplant (2007) 0.75
Dual monoclonal antibody therapy for the treatment of PTLD? Pediatr Transplant (2003) 0.75
Hypertension as an emerging risk factor for acute heart failure in Africa: comment on "The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries". Arch Intern Med (2012) 0.75
On improving outcomes and quality of dialysis care, and more. Am J Kidney Dis (2002) 0.75
Kidney disease in disadvantaged populations: An unconquered challenge. Clin Nephrol (2016) 0.75